The effectiveness of lutein in high myopic patients

The effectiveness of lutein in high myopic patients - Lutein and high myopia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025635

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high myopia

Interventions

Lutein administration group . Oral administration of Lutein 1capsule (20mg/capsule ) per day for 6 months Placebo administration group . Oral administration of sunflower oil 1capsule (180mg/capsule

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: high myopia patients

Exclusion criteria

Exclusion criteria: Patients who have serious retinal diseases such as glaucoma, age related macular degeneration and bleeding. Patients who have severe kidney disease , heart failure and hepatitis. People who have taken administration of lutein in 6 months.

Design outcomes

Primary

Measure	Time frame
The study of contrast sensitivity at baseline, 3-month and 6-month from baseline.	—

Secondary

Measure	Time frame
The study of visual acuity, concentration of macular pigmentation and ERG at baseline, 3-month and 6-month from baseline.	—

Countries

Japan

Contacts

Public ContactTakeshi Yoshida

Tokyo Medical and Dental University Ophthalmology

takec.oph@tmd.ac.jp0358035302

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026